Jill Broadfoot
Board Member
Cue Biopharma, Inc. (CUE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jill Broadfoot
Jill Broadfoot is recorded as Board Member at Cue Biopharma, Inc. (CUE). Cue Biopharma, Inc. reported in an 8-K filed June 2, 2026 that Jill Broadfoot resigned as member of the Board of Directors, effective May 29, 2026. Cue Biopharma, Inc. reported in an 8-K filed June 10, 2025 that Jill Broadfoot was appointed member of the board of directors, effective June 4, 2025.
“On May 29, 2026, Cue Biopharma, Inc. (the "Company") and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the "Board") and as members of the committees of the Board on which they serve, effective immediately.”
“On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the "Board") of Cue Biopharma, Inc. (the "Company"), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board, following the recommendation of the Corporate Governance and Nominating Committee of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-06-04–present
-
2025-06-04–2026-05-29
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Cue Biopharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Daniel R. Passeri CEO, Board Member
- Dr. Shao-Lee Lin CEO, Board Member
- Lucinda Warren CEO, CFO
- Usman Azam CEO, Board Member
- James Ahlers CFO
- Kerri Millar CFO
- Colin G. Sandercock General Counsel
- Sumita Ray General Counsel
- Michael Meluzio Chief Accounting Officer
- Daniel Camardo Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.